4-(2-Amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-2-pyrimidinamine

HCID 447961CAS 507487-89-0

기본 정보

표준 SMILES
Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1
InChIKey
DYTKVFHLKPDNRW-UHFFFAOYSA-N
분자식
C14H12N6O2S
평균 분자량
328.35 g/mol
단동위원소 질량
328.07424462

이름 및 식별자

우선 이름
4-(2-Amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-2-pyrimidinamine
IUPAC
4-methyl-5-[2-(3-nitroanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
영어명
Cdk2/9 Inhibitor
분자식
C14H12N6O2S
분자량
328.35

이름 및 동의어

[4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE2L9NBR9W3T2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-(3-nitrophenyl)pyrimidin-2-amine4-(2-Amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-2-pyrimidinamine(4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl)-(3-nitro-phenyl)-amine4-Methyl-5-(2-((3-nitrophenyl)amino)pyrimidin-4-yl)-1,3-thiazol-2-amine4-methyl-5-{2-[(3-nitrophenyl)amino]pyrimidin-4-yl}-1,3-thiazol-2-amineRefChem:512144Cdk2/9 Inhibitor507487-89-0CK7
이름 더 보기
CK7, 10 mM in DMSO4-Methyl-5-(2-((3-nitrophenyl)amino)-pyrimidin-4-yl)-thiazol-2-ylamineInhibitor,Nek1,CDK,CK-7,Cdk9,CK 7,kidney development,CK7,inhibit,Cyclin dependent kinase,Cdk2
4-methyl-5-[2-(3-nitroanilino)pyrimidin-4-yl]-1,3-thiazol-2-amineUNII-2L9NBR9W3TCHEMBL2984454-Methyl-5-(2-((3-nitrophenyl)amino)pyrimidin-4-yl)thiazol-2-amine1pxo2wevCDK2/9InhibitorCDK Inhibitor, 1

데이터베이스 식별자

CAS
507487-89-0
PubChem CID
447961
DTXSID
DTXSID30332265
ChEMBL
CHEMBL298445
UNII
2L9NBR9W3T
Nikkaji
J2.869.746E

물성

구조 계산 물성

XLogP
2.7
극성 표면적
151 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
8
회전 가능 결합 수
3
무거운 원자 수
23

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15

물리화학적 성질

끓는 점
590.5 · 590.5±60.0 °C(Predicted)
밀도
1.49 · 1.490±0.06 g/cm3(Predicted)
저장 조건
4 °C, · 4°C, protect from light
용해도
12.5 mg/mL · DMSO : 12.5 mg/mL (38.07 mM; ultrasonic and warming and heat to 60°C)
산도 계수 (pKa)
2.99 · 2.99±0.10(Predicted)
물리적 상태
Solid

안전 및 규제

안전 데이터

wgk
WGK 3
스토리지 클래스
11 - Combustible Solids

화학 및 산업

응용 분야

용도CDK2/9 Inhibitor has been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. Research suggests that monomeric CDK2 conformation can be selectively inhibited.

공급사18 곳

上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
上海微佳禾生物科技有限公司17502176150; 17502176150 · [email protected]
銳迪國際科技有限公司18024082417 · [email protected]
上海瀚香生物科技有限公司177-54423994 17754423994 · [email protected]
上海复青化学科技有限公司13816107857 · [email protected]

관련 반응

15건

연결된 노트

불러오는 중…